NCT02838381已完成不适用
Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 553
- 试验地点
- 2
- 主要终点
- frequency of peripheral T cell immune responses in the presence of antigenic peptides associated with digestive cancer
研究概览
简要总结
The aim of this study is to characterize the genetic and cellular immunological parameters of metastatic digestive cancer patients having short and long responses to chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For all patients:
- •signed written informed consent
- •For cohort A:
- •patient with metastatic colorectal cancer with first-line therapy by chemotherapy +/- surgery and with a disease-free survival > or = at 20 months
- •Ct-scan realized in the previous 4 weeks and showing no progression according to the Recist criteria v1.1
- •For cohort B:
- •patient treated for metastatic colorectal cancer and chemotherapy responder (obtention of an objective response according to the Recist criteria V1.1 in first-line therapy), with a disease-free survival < 10 months (disease progression must be confirmed by CT scan evaluation according to Recist v1.1 criteria)
- •For cohort C:
- •patients with no metastatic rectum cancer in complete remission after chemotherapy and/or radiotherapy
- •For cohort D:
- •patients with metastatic or locally advanced cancer in complete remission after treatment, non eligible in the other cohorts
排除标准
- •For all patients:
- •patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study
- •patient with a neurodegenerative disease
- •patient under guardianship, curator or under the protection of justice
结局指标
主要结局
frequency of peripheral T cell immune responses in the presence of antigenic peptides associated with digestive cancer
时间窗: at inclusion
progression-free survival
时间窗: within 5 years after the inclusion
time interval between the date of inclusion and the date of first progression or death from any cause.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Background of Different Phenotypes of Coeliac DiseaseDermatitis HerpetiformisCeliac DiseaseNCT05597904Tampere University Hospital3,500
已完成
不适用
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) PatientsMultiple MyelomaNCT05428163Assistance Publique Hopitaux De Marseille20
Unknown
不适用
Neoadjuvant Chemotherapy in Locally Advanced Breast CancerBreast CancerNCT00820690Barretos Cancer Hospital80
招募中
不适用
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic TumorsSolid Tumor, AdultSolid Tumor, ChildhoodHematologic CancerNCT05481502Gustave Roussy, Cancer Campus, Grand Paris160
进行中（未招募）
不适用
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer PatientsLung Cancer, Nonsmall CellNCT05415358Wake Forest University Health Sciences23